Opthea to Participate in the UBS Virtual Ophthalmology Day 2024

Rhea-AI Summary

Opthea (ASX/NASDAQ: OPT), a clinical-stage biopharmaceutical company focusing on novel therapies for retinal diseases like wet age-related macular degeneration (wet AMD), has announced its participation in the UBS Virtual Ophthalmology Day 2024. The event is scheduled for October 2, 2024.

Key details of Opthea's participation include:

• A fireside chat on Wednesday, October 2, 2024, at 4:00 PM ET
• CEO Frederic Guerard, PharmD, will be the presenter
• One-on-one investor meetings will be available
• A webcast link is provided for access to the fireside chat

The webcast will also be accessible through the 'Events & Presentations' section of Opthea's Investor Relations webpage at www.opthea.com.

News Market Reaction

+2.52%

1 alert

+2.52% News Effect

On the day this news was published, OPT gained 2.52%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

MELBOURNE, Australia and PRINCETON, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in a fireside chat and be available for one-on-one investor meetings at the UBS Virtual Ophthalmology Day 2024 being held on October 2, 2024.

UBS Virtual Ophthalmology Day 2024   

Fireside chat:	Wednesday, October 2, 2024, 4:00 PM ET
Presenter:	Frederic Guerard, PharmD, CEO
Webcast link:	https://kvgo.com/ubs/opthea-ltd-oct-2024

The webcast can also be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website, www.opthea.com.

About Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.

Investor Inquiries

PJ Kelleher 
LifeSci Advisors, LLC 
Email: pkelleher@lifesciadvisors.com
Phone: 617-430-7579 

Media Inquiries 

Silvana Guerci-Lena 
NorthStream Global Partners 
Email: silvana@nsgpllc.com 

Join our email database to receive program updates:  
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com   
Source: Opthea Limited

FAQ

When is Opthea (OPT) participating in the UBS Virtual Ophthalmology Day 2024?

Opthea (OPT) is participating in the UBS Virtual Ophthalmology Day on October 2, 2024. The company's fireside chat is scheduled for 4:00 PM ET on that day.

Who will represent Opthea (OPT) at the UBS Virtual Ophthalmology Day 2024?

Frederic Guerard, PharmD, the CEO of Opthea (OPT), will represent the company and present at the fireside chat during the UBS Virtual Ophthalmology Day 2024.

What type of retinal disease is Opthea (OPT) focusing on in their drug development?

Opthea (OPT) is developing novel therapies to treat highly prevalent and progressive retinal diseases, with a specific focus on wet age-related macular degeneration (wet AMD).

How can investors access Opthea's (OPT) presentation at the UBS Virtual Ophthalmology Day 2024?

Investors can access Opthea's (OPT) presentation via a webcast link provided in the press release. The webcast will also be available under the 'Events & Presentations' section of Opthea's Investor Relations website at www.opthea.com.